[HTML][HTML] Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study
Journal of Clinical Oncology, 2019•ncbi.nlm.nih.gov
PURPOSE Pembrolizumab monotherapy has demonstrated durable antitumor activity in
advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer
(NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data
provide the longest efficacy and safety follow-up for patients with NSCLC treated with
pembrolizumab monotherapy.
advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer
(NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data
provide the longest efficacy and safety follow-up for patients with NSCLC treated with
pembrolizumab monotherapy.
Abstract
PURPOSE
Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer (NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data provide the longest efficacy and safety follow-up for patients with NSCLC treated with pembrolizumab monotherapy.
ncbi.nlm.nih.gov